Overview

Phase I Study of Capecitabine in Combination With Cisplatin and Irinotecan

Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
1. To determine the safety and feasibility of administering Capecitabine with the combination of Cisplatin and Irinotecan. 2. To determine the Phase II recommended dose and toxicity profile of Capecitabine with the combination of Cisplatin and Irinotecan. 3. To study the biologic effect of pyrimidine inhibition on DNA repair after camptothecin therapy.
Phase:
Phase 1
Details
Lead Sponsor:
University of New Mexico
Treatments:
Camptothecin
Capecitabine
Cisplatin
Irinotecan